Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation
18.1.2021 17:00:00 EET | Business Wire | Press release
While 91% of organizations were successful in increasing security as a result of adopting cloud services, it remains a top concern for many. This finding comes from part two of the four-part Cloud Impact Study from Aptum, the global hybrid multi-cloud managed service provider. The report, titled The Security and Compliance Barricade , identifies common security, compliance and governance challenges impacting organizations undergoing cloud transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005035/en/
Aptum Cloud Impact Study Pt 2.: The Security and Compliance Barricade (Graphic: Business Wire)
The independent research reveals that more than half of survey respondents (51%) see security as the main driver behind cloud adoption. However, 38% cite security and data protection as the primary barrier to cloud transformation.
Security and compliance play a critical role
Part one of the Cloud Impact Study, Bridging the Cloud Gap , found most survey respondents plan to take a hybridized approach to their cloud infrastructure, with more than half (59%) of respondents saying they will reduce their on-premises infrastructure to some degree and increase public cloud deployments within the next 18-24 months. A further 66% intend to expand their private cloud workloads.
According to data found in today’s report, this expansion and diversification of infrastructure raises security and compliance issues among senior IT professionals, including:
- Control and governance (82%)
- Visibility through a single portal (81%)
- Ability to meet requirements of compliancy audits (80%)
“Organizations are enjoying a newfound agility as they embrace hybrid cloud solutions, but scattered workloads present a security concern," explains Craig Tavares, Global Head of Cloud at Aptum. “A cloud environment is only as secure as the polices and controls an organization has in place, which is why they need to be built into the formation of any cloud strategy. Although no single solution on its own can guarantee 100% security, especially in a multi/hybrid cloud approach, experienced partners can assist organizations in choosing the right combination of security technologies that compliments their workloads no matter where they are hosted and ensure visibility across disparate environments."
“Security teams are tasked with protecting a widening attack surface, often with limited budgets and resources, against bad actors who are employing the same sophisticated techniques as top cybersecurity providers,” said Dan Webb, VP of Partner Sales and Alliances, Alert Logic. “With the ubiquity of cloud and hybrid environments, containerization, and mobile, IoT, and other edge devices, the traditional notion of a perimeter is no more. To be effective, security solutions must enable total visibility across an organization’s IT estate to help organizations quickly identify, prioritize, and respond to all threats that surface.”
Together, Aptum and Alert Logic partner to safeguard business critical data across the infrastructure and application stack, merging security technology, threat intelligence and 24/7 security experts to deliver security outcomes to businesses in an as-a-service model.
The study’s results reinforce the importance of incorporating security into cloud architectures from design through to implementation and transformation. The results call for organizations to take a holistic approach to cloud architectures, with security principles embedded in the design. By doing this, businesses can mitigate threats and minimize risks as they arise to create an environment safer than any on-premise or legacy alternatives.
The full findings of part two of the Cloud Impact Study, The Security and Compliance Barricade, can be found here.
Aptum’s Cloud Impact Study was created from the opinions of 400 senior IT professionals in the US, Canada and UK across industries in financial services, IT, technology, telecommunications, manufacturing, retail, public and commercial sectors. The final two reports will focus on Costs and Budgets and Modernization Opportunities.
For part one of the report, Bridging the Cloud Gap, please visit here.
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Global Network solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America, Europe and the United Kingdom. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
Connect with Aptum
Official Blog| LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005035/en/
Contact information
Media Contact
Tonique Bedeau, Aptum Technologies
media@aptum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
